tradingkey.logo
tradingkey.logo
Search

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

ReutersSep 25, 2025 11:33 AM
facebooktwitterlinkedin
View all comments0

- Capricor Therapeutics Inc CAPR.O:

  • CAPRICOR THERAPEUTICS PROVIDES REGULATORY UPDATE ON DERAMIOCEL PROGRAM FOR DUCHENNE MUSCULAR DYSTROPHY FOLLOWING TYPE A MEETING

  • CAPRICOR THERAPEUTICS INC - FDA AND CAPRICOR ALIGN ON HOPE-3 TRIAL ENDPOINTS

  • CAPRICOR THERAPEUTICS INC - COMPANY TO RESUBMIT CRL RESPONSE UNDER CURRENT BLA

  • CAPRICOR THERAPEUTICS INC - HOPE-3 TRIAL COMPLETED, DATA EXPECTED MID-Q4 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI